Nyxoah SA (NYXH) News
Filter NYXH News Items
NYXH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NYXH News Highlights
- NYXH's 30 day story count now stands at 2.
- Over the past 11 days, the trend for NYXH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- SA, LAW and OSA are the most mentioned tickers in articles about NYXH.
Latest NYXH News From Around the Web
Below are the latest news stories about NYXOAH SA that investors may wish to consider to help them evaluate NYXH as an investment opportunity.
Nyxoah Appoints Mr. Daniel Wildman to its Board of DirectorsNyxoah Appoints Mr. Daniel Wildman to its Board of Directors Mont-Saint-Guibert, Belgium – January 9, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has appointed Mr. Daniel Wildman as an Independent Director to its Board of Directors*. Mr. Wildman is a 40-year veteran of the m |
Information on the total number of voting rights and sharesREGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), December 29, 2022, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the issue of new warrants. Share capital: EUR 4,440,069.16 Total number of securities carrying voting rights: 25,846,279 (all ordinary shares) Total number |
Nyxoah Files Shelf Registration Statement and Announces At-the-Market Equity Offering ProgramINSIDE INFORMATIONREGULATED INFORMATION Nyxoah Files Shelf Registration Statement and Announces At-the-Market Equity Offering Program Mont-Saint-Guibert, Belgium – December 22, 2022, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has filed a $200 million shelf registration statement |
Nyxoah to Participate in the Piper Sandler 34th Annual Healthcare ConferenceNyxoah to Participate in the Piper Sandler 34th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – November 17, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference, which takes place November 2 |
Wall Street Analysts See a 240% Upside in Nyxoah SA (NYXH): Can the Stock Really Move This High?The mean of analysts' price targets for Nyxoah SA (NYXH) points to a 240% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Nyxoah S.A. (NYXH) Q3 2022 Results - Earnings Call TranscriptNyxoah S.A. (NASDAQ:NASDAQ:NYXH) Q3 2022 Results Earnings Conference Call November 08, 2022, 04:30 PM ET Company Participants Jeremy Feffer - Vice President, Investor Relations Olivier… |
Nyxoah Reports Third Quarter 2022 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Third Quarter 2022 Financial and Operating Results DREAM US pivotal 12-month clinical data expected in fall of 2023 Mont-Saint-Guibert, Belgium – November 8, 2022, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the quar |
Nyxoah Announces Change to Board of DirectorsNyxoah Announces Change to Board of Directors Mont-Saint-Guibert, Belgium – October 24, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Raymond Cohen resigned as member of the board of directors of the Company effective October 18, 2022. About NyxoahNyxoah is a medical technology |
Nyxoah to Participate in the Jefferies London Healthcare ConferenceNyxoah to Participate in the Jefferies London Healthcare Conference Mont-Saint-Guibert, Belgium – October 20, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies London Healthcare Conference, which takes place November 15-17, 2022, at The |
Nyxoah to Release Third Quarter Financial Results on November 8, 2022Nyxoah to Release Third Quarter Financial Results on November 8, 2022 Mont-Saint-Guibert, Belgium – October 18, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter of 2022 on Tuesday, November 8, 2022, after market close |